Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Breast Neoplasms: early-phase trial registry
35 of 98 indexed Breast Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #141 of 28,707 conditions by registered trial count.
98 US clinical trials · 35 currently recruiting · #141 of 28,707 conditions by registered trial count
Breast Neoplasms: 98 US clinical trials tracked, 35 recruiting.
Breast Neoplasms is the subject of 98 registered US clinical trials on ClinicalTrials.gov, 35 of them currently open to new participants. 20 are in Phase 3-4 (later-stage) and 51 in Phase 1-2 (earlier-stage). The most active sponsor is Pfizer, running 10 of these trials.
Enrollment posture brief
Registry condition breast-neoplasms
OPEN 35 | RECR 36% | LATE 20 | EARLY 51 | RANK #141 | SPON 10
Volume-matched condition peers
Nearest open-share peer: Acute Respiratory Failure (36% recruiting · 14 trials)
Breast Neoplasms lists 35 open slots (36% of 98 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Breast Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Breast Neoplasms is recruiting below its size-band peers.
35 of 98 indexed trials (35.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Breast Neoplasms trials is spread across many organizations.
Pfizer accounts for 10 of 98 trials (10.2%). 60 distinct sponsors appear on at least one study for this condition label.
-
Typical Breast Neoplasms enrolment sits around 134 participants.
Median target enrolment is 134 among the 98 trials that report a genuine target (sentinel values excluded). 40 of those (40.8%) plan for fewer than 100 participants.
-
Breast Neoplasms research is mostly interventional.
85 interventional and 13 observational studies make up this index (86.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
98 total, page 1 of 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
QuantumLeap Healthcare Collaborative
NCT01042379
Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
UNC Lineberger Comprehensive Cancer Center
NCT07214610
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Merck Sharp & Dohme
NCT06966700
Biennial CEM in Women With a Personal History of Breast Cancer
Wendie Berg
NCT06105749
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Merck Sharp & Dohme
NCT06312176
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Merck Sharp & Dohme
NCT07060807
Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer
Saint John's Cancer Institute
NCT04603209
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
NCT07174336
A Study of Breast Cancer Risk Factors and Outcomes of People in Florida
Memorial Sloan Kettering Cancer Center
NCT06780176
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
BioNTech SE
NCT07173751
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
Uppsala University
NCT04722692
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Bristol-Myers Squibb
NCT06926868
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Eli Lilly and Company
NCT07114601
A Registry Study of Breast Microseed Treatment
Concure Oncology-Breast Microseed
NCT02701244
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Merck Sharp & Dohme
NCT06797635
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
Washington University School of Medicine
NCT00353483
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Kristina A. Fanucci
NCT07222215
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Eli Lilly and Company
NCT07213791
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Circle Pharma
NCT06577987
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT06157892
Breast Cancer, Reasoning, and Activity Intervention
Mayo Clinic
NCT04816006
A Study of DM001 in Patients With Advanced Solid Tumors
Xadcera Biopharmaceutical (Suzhou) Co.
NCT06475937
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Pfizer
NCT06966453
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
Rutgers, The State University of New Jersey
NCT07158164
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Atossa Therapeutics
NCT05607004
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Merck Sharp & Dohme
NCT06686394
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Stemline Therapeutics
NCT05386108
Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
Brown University
NCT06974604
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Washington University School of Medicine
NCT02476786
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
Baylor Research Institute
NCT06517212
Focused Ultrasound and Gemcitabine in Breast Cancer
Patrick Dillon, MD
NCT04796220
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
GlaxoSmithKline
NCT04641247
The Intestinal Microbiome in Triple Negative Breast Cancer Treated with Immunotherapy
Pennington Biomedical Research Center
NCT06318507
Dissemination of BREASTChoice AIM1-B
UNC Lineberger Comprehensive Cancer Center
NCT07396766
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
NCT06623396
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company
NCT05514054
Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western Pennsylvania
Wendie Berg
NCT04085510
Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers
Memorial Sloan Kettering Cancer Center
NCT00579163
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
AstraZeneca
NCT05113251
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
Eli Lilly and Company
NCT04975308
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Eli Lilly and Company
NCT02107703
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Pfizer
NCT04557449
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
Merck Sharp & Dohme
NCT04895358
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
BicycleTx Limited
NCT04561362
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation
Alliance for Clinical Trials in Oncology
NCT04711109
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
National Cancer Institute (NCI)
NCT02484404
The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)
University of Michigan Rogel Cancer Center
NCT02400190
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Eli Lilly and Company
NCT02057133
Lifestyle, Exercise, and Nutrition Study Early After Diagnosis
Yale University
NCT03314688
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
NCT00600496
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 29 |
| Phase 2 | 22 |
| Phase 3 | 19 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Breast Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Breast Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Breast Neoplasms page
98 registered trials, 35 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 35 Breast Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pfizer sponsors the most Breast Neoplasms trials on record, review their full trial history before evaluating a specific study. See Pfizer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Breast Neoplasms condition card totals 98 registered trials; most-linked intervention Anastrozole; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.